Physician profile
Hailey E Brogan
NPI 1083117766
$488.30
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $246 · 2023: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $88.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.31 | 2021-2022 | |
| Genzyme Corporation | $51.34 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $48.66 | 2022-2023 | Fasenra |
| Teva Pharmaceuticals USA, INC. | $45.96 | 2022 | |
| Amgen INC. | $37.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.58 | 2023 | Spevigo |
| Daiichi Sankyo INC. | $24.72 | 2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $20.55 | 2022 | |
| Melinta Therapeutics, LLC | $18.95 | 2023 | Kimyrsa |
| Horizon Therapeutics Plc | $16.45 | 2022 | |
| Merck Sharp & Dohme LLC | $13.72 | 2022 | |
| Abbvie INC. | $13.20 | 2022 | |
| Glaxosmithkline, LLC. | $12.33 | 2022 | |
| Pharmacosmos Therapeutics INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Brogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.